Pedro Miguel Lacal

7PUBLICATIONS
13CO-AUTHORS
Predictive and prognostic markersInnate immunityMolecular targetsMedical infection agents (incl. prions)Gene and molecular therapy
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (7)

|Nov 26, 2022
The Anti-Vascular Endothelial Growth Factor Receptor 1 (VEGFR-1) D16F7 Monoclonal Antibody Inhibits Melanoma Adhesion to Soluble VEGFR-1 and Tissue Invasion in Response to Placenta Growth Factor.

Maria Grazia Atzori, Claudia Ceci, Federica Ruffini

|Aug 12, 2022
Circulating miR-1246 and miR-485-3p as Promising Biomarkers of Clinical Response and Outcome in Melanoma Patients Treated with Targeted Therapy.

Lauretta Levati, Cristian Bassi, Simona Mastroeni

|Oct 13, 2021
At the Cutting Edge against Cancer: A Perspective on Immunoproteasome and Immune Checkpoints Modulation as a Potential Therapeutic Intervention.

Grazia R Tundo, Diego Sbardella, Francesco Oddone

|Nov 20, 2020
Targeting Tumor-Associated Macrophages to Increase the Efficacy of Immune Checkpoint Inhibitors: A Glimpse into Novel Therapeutic Approaches for Metastatic Melanoma.

Claudia Ceci, Maria Grazia Atzori, Pedro Miguel Lacal

|Nov 06, 2020
PDIA3 Expression in Glioblastoma Modulates Macrophage/Microglia Pro-Tumor Activation.

Marta Chiavari, Gabriella Maria Pia Ciotti, Francesco Canonico

|Apr 26, 2020
Multiple Sclerosis Treatment and Melanoma Development.

Maria Luigia Carbone, Pedro Miguel Lacal, Serena Messinese

Pageof 2

Frequent Collaborators

5 joint publications

Grazia Graziani

1 joint publications

Lucio Tentori

1 joint publications

Grazia R Tundo

1 joint publications

Cristina Maria Failla